Quantitative 177Lu-DOTATATE SPECT/CT is predictive of 6-month PRRT morphological response in midgut neuroendocrine tumors: a pilot study

Abstract Background peptide receptor radionuclide therapy with 177Lu-DOTATATE has become an established second-line treatment for patients with advanced small intestine neuroendocrine tumors (siNET). Treatment efficacy is assessed several months after the end of treatment and is based on RECIST crit...

Full description

Saved in:
Bibliographic Details
Main Authors: Iness Megherbi, Christopher Hoog, Marine Perrier, Hedia Brixi, Guillaume Cadiot, Christine Hoeffel-Fornes, David Morland
Format: Article
Language:English
Published: SpringerOpen 2025-05-01
Series:EJNMMI Research
Subjects:
Online Access:https://doi.org/10.1186/s13550-025-01250-6
Tags: Add Tag
No Tags, Be the first to tag this record!